How Women’s Health Conversations With Investors Have Evolved
The funding landscape for women's health companies is getting better, partially due to more women getting promoted at VC firms and social media, execs said during a recent panel.
Neuro-focused Arkuda raises $64M as dementia drug moves closer to the clinic
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited form of dementia. If the biotech’s approach works, it could also have applications in other neurodegenerative conditions such as Alzheimer’s and Parkinson’s.
The Impact Brands: Empowering Wellness Through Natural and Holistic Solutions
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
AI-driven Congruence Therapeutics gets $50M to stabilize misfolded proteins
Biotech startup Congruence Therapeutics is developing novel drugs that treat disease by stabilizing misfolded proteins. Key to the company’s approach is a computational platform that discovers and designs these small molecule stabilizers.
SoftBank leads Dewpoint’s $150M round as multiple programs march toward clinic
Dewpoint is developing drugs targeting biomolecular condensates, tiny droplets in cells that contain proteins and nucleic acids. Dysfunction of these organelles can play a role in a wide range of diseases, including neurodegenerative disorders and cardiovascular disease.
Following Janssen flu deal, Leyden Labs gets $140M led by Casdin Capital and GV
Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.
AI firm BenchSci raises $50M for tech that takes waste out of preclinical research
BenchSci’s technology uses artificial intelligence to make drug R&D faster and more efficient. Big pharmaceutical companies and clinical-stage biotechs are current users of the software, and BenchSci said it will use its new funding to expand the technology.
Unlocking Transparency in PBM Pricing
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Psychedelic biotech Eleusis enters SPAC deal to take depression drug to the clinic
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
ImmPACT Bio reels in $111M to prevent tumor escape with novel cell therapies
Despite the targeted approach of some cancer treatments, tumors can find ways to escape, leading patients to relapse. ImmPACT Bio will apply its Series B financing toward the development of cell therapies designed to prevent tumor escape.
Regenerative med biotech ProKidney inks merger to get $825M for CKD cell therapy
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
J&J’s investment arm joins $150M investment in digital health firm Verana
Digital health company Verana Health has raised $150 million. The company said it will use the new capital to expand its technology, which is used by physicians and pharmaceutical companies.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Eli Lilly joins Verge Genomics’ $98M round as AI-discovered ALS drug nears clinic
Three life science companies unveiled Series B rounds of funding Thursday, early Christmas gifts that top $219 million combined. Along with Verge Genomics, the other companies that raised new capital are Tasso and Brainomix.
Cancer & immunology biotech Odyssey embarks with $218M, Gary Glick at helm
Odyssey Therapeutics is the latest startup formed by serial biotech entrepreneur Gary Glick. Odyssey’s destination is oncology and immunology drugs that address novel disease targets, and the biotech now has $218 million in Series A financing to fuel the journey.
Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design
Nabla Bio emerged from the lab of famed Harvard scientist George Church last year, and its antibody discovery technology has already led to five partnerships with pharma and biotech companies. The startup just closed an $11 million seed financing that will support further development of its technology.
Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies
AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.
Curie Therapeutics unveils $75M to widen scope of radiopharmaceuticals for cancer
Radiopharmaceuticals deploy radiation to damage cancer DNA, but Curie Therapeutics sees these therapies opening the door to a wider range of ways to kill tumors. The startup has raised $75 million in Series A financing to advance its research.